Acurx Pharmaceuticals, Inc. (ACXP) News
Follow Acurx Pharmaceuticals, Inc. (ACXP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Acurx Pharmaceuticals Price Target Maintained With a $31.00/Share by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 29, 2026, 03:53 PM UTC
L
HC Wainwright & Co. reiterates Buy rating on Acurx Pharmaceuticals, $31 price target
HC Wainwright & Co. reiterated their Buy rating on Acurx Pharmaceuticals's stock with a price target of $31.00.The price target implies an upside of 2213.4% from the Sep 28 close of $1.34.Key takeaways from the analyst n
REGULATION | Sep 29, 2026, 03:43 PM UTC
L
Acurx Pharmaceuticals, Inc. (ACXP) Enrolls First Patient in PATHFINDER rCDI Trial
Acurx enrolled the first patient in PATHFINDER, a fully funded ~20-patient Phase 2 open-label rCDI study of ibezapolstat intended to support a potential NDA based on a single Phase 3 trial. A larger non-inferiority Phase
NEWS | Sep 29, 2026, 12:02 PM UTC
L
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
STATEN ISLAND, N.Y., Sept. 29, 2026 // -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacteria
NEWS | Sep 29, 2026, 12:01 PM UTC
M
ACXP enrolls first patient in PATHFINDER ibezapolstat trial
Acurx Pharmaceuticals (ACXP) says the first patient has been enrolled in its PATHFINDER clinical trial of ibezapolstat in multiply-recurrent C. difficile infection.
EQUITY | Sep 29, 2026, 12:01 PM UTC
H
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call
Acurx Pharmaceuticals (NASDAQ: ACXP ) reported second-quarter financial results on Friday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings
LIVE | Sep 18, 2026, 12:03 PM UTC
L
Acurx Pharmaceuticals gets FDA conditional acceptance and USPTO trademark allowance
Acurx Pharmaceuticals (ACXP) receives FDA conditional acceptance and a USPTO trademark allowance for its Ibezapolstat brand name.
REGULATION | Aug 17, 2026, 12:02 PM UTC
L
ACXP Granted Patents in Japan and Mexico
Acurx Pharmaceuticals is granted new patents in Japan and Mexico for DNA Polymerase IIIC Inhibitor Antibiotics
EQUITY | Aug 12, 2026, 12:02 PM UTC
H
ACXP ACXP - FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including t
ACXP ACXP - FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single- Phase 3-Trial Registration Plan and a Trial Design to
EQUITY | Aug 03, 2026, 12:01 PM UTC